Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Colistin (Polymyxin E) vs Micafungin (Mycamine)
An educational, source-based comparison of Colistin (Polymyxin E) and Micafungin (Mycamine) — how each peptide works, what it's researched for, and what to know before going deeper.
Last-resort lipopeptide antibiotic for multidrug-resistant Gram-negatives.
Cationic cyclic lipopeptide that disrupts the outer membrane of Gram-negative bacteria by binding lipid A of LPS, causing membrane permeability and cell death.
- Carbapenem-resistant Acinetobacter, Klebsiella, Pseudomonas
- • FDA-approved.
- • Nephrotoxicity and neurotoxicity dose-limiting.
Echinocandin antifungal for Candida infections and prophylaxis.
Semi-synthetic echinocandin lipopeptide that inhibits β-1,3-D-glucan synthase, fungicidal against most Candida species.
- Invasive candidiasis
- Esophageal candidiasis
- Stem-cell transplant prophylaxis
- • FDA-approved.
- • Generally well-tolerated; monitor LFTs.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Colistin (Polymyxin E) | Colistin in MDR Gram-negative infections | Clinical Infectious Diseases | 2005 | Effective salvage therapy with manageable nephrotoxicity in modern dosing. |
| Micafungin (Mycamine) | Micafungin vs liposomal amphotericin | Lancet | 2007 | Non-inferior with better safety profile. |
Side-effect & safety grid
- FDA-approved.
- Nephrotoxicity and neurotoxicity dose-limiting.
- FDA-approved.
- Generally well-tolerated; monitor LFTs.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Colistin (Polymyxin E) vs Micafungin (Mycamine) — Key differences
- Class: Colistin (Polymyxin E) is classified as Polymyxin · Infectious Disease, while Micafungin (Mycamine) is Echinocandin · Antifungal.
- Primary research focus: Colistin (Polymyxin E) — carbapenem-resistant acinetobacter, klebsiella, pseudomonas; Micafungin (Mycamine) — invasive candidiasis.
- Tag: FDA-Approved · Antibiotic vs FDA-Approved · Antifungal.